Tudor Investment Corp
PRLD icon

Tudor Investment Corp’s Prelude Therapeutics PRLD Stock Holding History

Tudor Investment Corp’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-48,624
Closed -$1.47M – 1567
2020
Q3 		$1.47M Buy
+48,624
New +$1.37M 0.06% 416

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Tudor Investment Corp's PRLD Position: Q4 2020 in Review

Tudor Investment Corp sold out of Prelude Therapeutics (PRLD) in Q4 2020, closing a stake of 48,624 shares — an estimated $1.47M sold.

Tudor Investment Corp first reported a position in PRLD in Q3 2020 and held it in 1 quarter. The position peaked at $1.47M in Q3 2020. 51 funds tracked by Wall St. Rank hold PRLD as of Q4 2020.

  • Tudor Investment Corp reported no remaining Prelude Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Tudor Investment Corp sold 48,624 Prelude Therapeutics shares in Q4 2020, an estimated $1.47M.
  • Tudor Investment Corp first reported a position in Prelude Therapeutics in Q3 2020 and held it in 1 quarter.
  • Tudor Investment Corp's Prelude Therapeutics position peaked at $1.47M in Q3 2020.
  • 51 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2020.

Based on Tudor Investment Corp's 13F filing for Q4 2020, filed 16 Feb 2021.